The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:
EC 3.5.* (hydrolases acting on non-peptide C-N bonds) inhibitor
Enkephalin, Ala(2)-MePhe(4)-Gly(5)- inhibits the reaction [OPRM1 protein affects the reaction [Potassium results in increased abundance of Catecholamines]]; Enkephalin, Ala(2)-MePhe(4)-Gly(5)- inhibits the reaction [OPRM1 protein affects the reaction [Potassium results in increased transport of Barium]]; Enkephalin, Ala(2)-MePhe(4)-Gly(5)- inhibits the reaction [OPRM1 protein results in increased transport of Barium]; omega-Conotoxin GVIA inhibits the reaction [Enkephalin, Ala(2)-MePhe(4)-Gly(5)- inhibits the reaction [OPRM1 protein results in increased transport of Barium]]
Dactinomycin inhibits the reaction [Cadmium Chloride results in increased expression of HSPA5 protein]; Dactinomycin inhibits the reaction [Cadmium results in increased expression of HSPA5 protein]
INS protein results in increased uptake of 2-(methylamino)isobutyric acid Dimercaprol inhibits the reaction [oxophenylarsine inhibits the reaction [INS protein results in increased uptake of 2-(methylamino)isobutyric acid]]; oxophenylarsine inhibits the reaction [INS protein results in increased uptake of 2-(methylamino)isobutyric acid]
Amiloride inhibits the reaction [[Asbestos, Crocidolite results in increased activity of PLAU protein] which results in increased cleavage of PLG protein]; Amiloride inhibits the reaction [[Asbestos, Serpentine results in increased activity of PLAU protein] which results in increased cleavage of PLG protein]
Amiloride inhibits the reaction [[Asbestos, Crocidolite results in increased activity of PLAU protein] which results in increased cleavage of PLG protein]; Amiloride inhibits the reaction [[Asbestos, Serpentine results in increased activity of PLAU protein] which results in increased cleavage of PLG protein]; Amiloride inhibits the reaction [Asbestos, Crocidolite results in increased cleavage of PLG protein]; Amiloride inhibits the reaction [Asbestos, Serpentine results in increased cleavage of PLG protein]
1,10-phenanthroline inhibits the reaction [ENPEP protein results in increased hydrolysis of Aspartame]; amastatin inhibits the reaction [ENPEP protein results in increased hydrolysis of Aspartame]; Calcium Chloride promotes the reaction [ENPEP protein results in increased hydrolysis of Aspartame]
1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid inhibits the reaction [Adenosine Triphosphate promotes the reaction [calyculin A results in increased phosphorylation of MYL9 protein]]; [Calcium co-treated with 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid] results in decreased phosphorylation of MYL9 protein
belnacasan inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of GSDMD mRNA]; belnacasan inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of GSDMD protein]
belnacasan inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of IL18 mRNA]; belnacasan inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of IL18 protein]
belnacasan inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of IL1B mRNA]; belnacasan inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of IL1B protein]
Brimonidine Tartrate results in increased phosphorylation of CREB1 protein N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Brimonidine Tartrate results in increased phosphorylation of CREB1 protein]
Carvedilol results in decreased expression of EDN1 protein Glyburide inhibits the reaction [Carvedilol results in decreased expression of EDN1 protein]
Chlorogenic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of CXCL8 protein]; Chlorogenic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL8 mRNA]
Chlorogenic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL6 protein]; Chlorogenic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]
Chloroquine results in increased expression of SQSTM1 protein Chloroquine inhibits the reaction [ochratoxin A results in decreased expression of SQSTM1 protein]
Chlortetracycline inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; daidzein inhibits the reaction [SLCO1A2 protein results in increased uptake of Chlortetracycline]; epigallocatechin gallate inhibits the reaction [SLCO1A2 protein results in increased uptake of Chlortetracycline]; Genistein inhibits the reaction [SLCO1A2 protein results in increased uptake of Chlortetracycline]; naringin inhibits the reaction [SLCO1A2 protein results in increased uptake of Chlortetracycline]; Oxytetracycline inhibits the reaction [SLCO1A2 protein results in increased uptake of Chlortetracycline]
Cocaine results in increased expression of EDN1 protein 1,3-ditolylguanidine inhibits the reaction [Cocaine results in increased expression of EDN1 protein]; Haloperidol inhibits the reaction [Cocaine results in increased expression of EDN1 protein]
Cyclosporine results in decreased expression of OPA1 protein Vitamin E inhibits the reaction [Cyclosporine results in decreased expression of OPA1 protein]
SLC2A1 protein results in decreased susceptibility to Cyclosporine Amiloride promotes the reaction [Cyclosporine results in increased expression of SLC2A1 mRNA]; Phloretin promotes the reaction [Cyclosporine results in increased expression of SLC2A1 mRNA]; Phloretin promotes the reaction [Cyclosporine results in increased expression of SLC2A1 protein] Cyclosporine results in increased expression of SLC2A1 mRNA; Cyclosporine results in increased expression of SLC2A1 protein
[Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] promotes the reaction [bisphenol A results in decreased expression of CAT protein]; [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of CAT mRNA; [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of CAT protein
[Ethanol co-treated with Folic Acid deficiency] results in increased activity of CBS protein Folic Acid deficiency results in increased activity of CBS protein
[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [bisphenol A results in decreased expression of DNMT3A mRNA]; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of DNMT3A mRNA
[Ethanol co-treated with Folic Acid deficiency] results in increased activity of GCLC protein; [Ethanol co-treated with Folic Acid deficiency] results in increased expression of GCLC mRNA
[Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of GPX1 mRNA; [bisphenol A co-treated with [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12]] results in increased expression of GPX1 mRNA
[Ethanol co-treated with Folic Acid deficiency] results in increased activity of GSR protein; [Ethanol co-treated with Folic Acid deficiency] results in increased expression of GSR mRNA Folic Acid deficiency results in increased activity of GSR protein Folic Acid deficiency results in increased expression of GSR mRNA
[Ethanol co-treated with Folic Acid deficiency] results in increased activity of GSS protein; [Ethanol co-treated with Folic Acid deficiency] results in increased expression of GSS mRNA
[Betaine co-treated with Choline co-treated with Folic Acid co-treated with bisphenol A] results in increased methylation of GYS1 promoter; [Betaine co-treated with Choline co-treated with Folic Acid] results in decreased expression of GYS1 mRNA; [Betaine co-treated with Choline co-treated with Folic Acid] results in increased methylation of GYS1 promoter
[Ethanol co-treated with Folic Acid deficiency] results in increased expression of GSTA1 mRNA Folic Acid deficiency results in increased expression of GSTA1 mRNA
[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [bisphenol A results in decreased expression of SLC15A1 mRNA]; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [bisphenol A results in decreased methylation of SLC15A1 promoter]; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of SLC15A1 mRNA
[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid co-treated with bisphenol A] results in increased expression of SLC5A1 mRNA; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of SLC5A1 mRNA
Folic Acid deficiency results in decreased activity of SOD1 protein [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of SOD1 mRNA; [Ethanol co-treated with Folic Acid deficiency] results in decreased activity of SOD1 protein
[Ethanol co-treated with Folic Acid deficiency] results in increased activity of SOD2 protein Folic Acid deficiency results in increased activity of SOD2 protein; Folic Acid results in increased activity of SOD2 protein
fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of APAF1 mRNA]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of APAF1 protein] fumonisin B1 results in increased expression of APAF1 mRNA; fumonisin B1 results in increased expression of APAF1 protein
[fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX mRNA; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX protein; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX protein]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of BAX mRNA]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of BAX protein]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of BAX mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of BAX protein]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX mRNA] fumonisin B1 results in increased expression of BAX mRNA; fumonisin B1 results in increased expression of BAX protein
fumonisin B1 results in decreased expression of BCL2 mRNA; fumonisin B1 results in decreased expression of BCL2 protein [Acetylcysteine co-treated with fumonisin B1 co-treated with deoxynivalenol] results in increased expression of BCL2 protein; [Acetylcysteine co-treated with fumonisin B1] results in increased expression of BCL2 protein; [Acetylcysteine co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of BCL2 protein; [fumonisin B1 co-treated with deoxynivalenol] results in decreased expression of BCL2 mRNA; [fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 mRNA; [fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 protein; [fumonisin B1 co-treated with Zearalenone co-treated with deoxynivalenol] results in decreased expression of BCL2 protein; [fumonisin B1 co-treated with Zearalenone] results in decreased expression of BCL2 mRNA; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in decreased expression of BCL2 mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 protein]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with Zearalenone] results in decreased expression of BCL2 mRNA]; Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [Zearalenone results in decreased expression of BCL2 mRNA]]; fumonisin B1 inhibits the reaction [deoxynivalenol results in decreased expression of BCL2 protein]; fumonisin B1 inhibits the reaction [Zearalenone inhibits the reaction [deoxynivalenol results in decreased expression of BCL2 mRNA]]; fumonisin B1 promotes the reaction [ochratoxin A results in decreased expression of BCL2 mRNA]; fumonisin B1 promotes the reaction [ochratoxin A results in decreased expression of BCL2 protein]; fumonisin B1 promotes the reaction [Zearalenone results in decreased expression of BCL2 mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in decreased expression of BCL2 mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in decreased expression of BCL2 protein]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 mRNA]; Zearalenone inhibits the reaction [fumonisin B1 inhibits the reaction [deoxynivalenol results in decreased expression of BCL2 protein]]; Zearalenone inhibits the reaction [fumonisin B1 promotes the reaction [Zearalenone results in decreased expression of BCL2 mRNA]]
N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of CASP1 mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of CASP1 protein]
3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [fumonisin B1 results in increased expression of CASP3 mRNA]; 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [fumonisin B1 results in increased expression of CASP3 protein]; [fumonisin B1 co-treated with deoxynivalenol] results in increased expression of CASP3 mRNA; [fumonisin B1 co-treated with deoxynivalenol] results in increased expression of CASP3 protein; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 mRNA; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein modified form; [fumonisin B1 co-treated with Zearalenone] promotes the reaction [deoxynivalenol results in increased expression of CASP3 protein]; [fumonisin B1 co-treated with Zearalenone] results in increased expression of CASP3 mRNA; [fumonisin B1 co-treated with Zearalenone] results in increased expression of CASP3 protein; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein modified form]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with Zearalenone] promotes the reaction [deoxynivalenol results in increased expression of CASP3 protein]]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with Zearalenone] results in increased expression of CASP3 protein]; Acetylcysteine inhibits the reaction [deoxynivalenol promotes the reaction [[fumonisin B1 co-treated with Zearalenone] results in increased expression of CASP3 mRNA]]; Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of CASP3 mRNA]]; deoxynivalenol promotes the reaction [[fumonisin B1 co-treated with Zearalenone] results in increased expression of CASP3 mRNA]; fumonisin B1 promotes the reaction [deoxynivalenol promotes the reaction [Zearalenone results in increased expression of CASP3 mRNA]]; fumonisin B1 promotes the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP3 mRNA]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP3 protein modified form]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP3 protein]; fumonisin B1 promotes the reaction [Zearalenone promotes the reaction [deoxynivalenol results in increased expression of CASP3 mRNA]]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP3 mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP3 protein modified form]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP3 protein]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 mRNA]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein modified form]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein]; Zearalenone promotes the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of CASP3 mRNA] fumonisin B1 results in increased expression of CASP3 mRNA; fumonisin B1 results in increased expression of CASP3 protein; fumonisin B1 results in increased expression of CASP3 protein modified form
[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 mRNA; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein modified form; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein modified form]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP9 mRNA]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP9 protein modified form]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP9 protein]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP9 mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP9 protein modified form]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP9 protein]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 mRNA]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein modified form]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein] fumonisin B1 results in increased expression of CASP9 mRNA; fumonisin B1 results in increased expression of CASP9 protein; fumonisin B1 results in increased expression of CASP9 protein modified form
[deoxynivalenol co-treated with fumonisin B1] results in increased expression of CCL2 mRNA; [deoxynivalenol co-treated with nivalenol co-treated with fumonisin B1] results in increased expression of CCL2 mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of CCL2 mRNA; [deoxynivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of CCL2 mRNA; [nivalenol co-treated with fumonisin B1] results in increased expression of CCL2 mRNA; [Zearalenone co-treated with fumonisin B1] results in increased expression of CCL2 mRNA; fumonisin B1 metabolite inhibits the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CCL2 mRNA]; fumonisin B1 promotes the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CCL2 mRNA] fumonisin B1 results in decreased expression of CCL2 mRNA fumonisin B1 metabolite results in increased expression of CCL2 mRNA; fumonisin B1 results in increased expression of CCL2 mRNA
fumonisin B1 results in increased expression of CCL20 mRNA fumonisin B1 metabolite inhibits the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CCL20 mRNA]; fumonisin B1 promotes the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CCL20 mRNA]
[deoxynivalenol co-treated with fumonisin B1] results in increased expression of CXCL8 mRNA; [deoxynivalenol co-treated with nivalenol co-treated with fumonisin B1] results in increased expression of CXCL8 mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of CXCL8 mRNA; [deoxynivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of CXCL8 mRNA; [nivalenol co-treated with fumonisin B1] results in increased expression of CXCL8 mRNA; [nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of CXCL8 mRNA; [Zearalenone co-treated with fumonisin B1] results in increased expression of CXCL8 mRNA; fumonisin B1 metabolite inhibits the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CXCL8 mRNA]; fumonisin B1 promotes the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CXCL8 mRNA] fumonisin B1 results in increased expression of CXCL8 mRNA
[deoxynivalenol co-treated with fumonisin B1] results in increased expression of CYCS mRNA; [Zearalenone co-treated with fumonisin B1] results in increased expression of CYCS mRNA; Acetylcysteine inhibits the reaction [deoxynivalenol promotes the reaction [[Zearalenone co-treated with fumonisin B1] results in increased expression of CYCS mRNA]]; Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [deoxynivalenol promotes the reaction [Zearalenone results in increased expression of CYCS mRNA]]]; Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [[deoxynivalenol co-treated with fumonisin B1] results in increased expression of CYCS mRNA]]; deoxynivalenol promotes the reaction [[Zearalenone co-treated with fumonisin B1] results in increased expression of CYCS mRNA]; fumonisin B1 promotes the reaction [deoxynivalenol promotes the reaction [Zearalenone results in increased expression of CYCS mRNA]]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CYCS mRNA]; Zearalenone promotes the reaction [[deoxynivalenol co-treated with fumonisin B1] results in increased expression of CYCS mRNA]
belnacasan inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of GSDMD mRNA]; belnacasan inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of GSDMD protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of GSDMD mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of GSDMD protein]
Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [deoxynivalenol results in decreased activity of GSR protein]]; Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [Zearalenone promotes the reaction [deoxynivalenol results in decreased activity of GSR protein]]]; Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [fumonisin B1 promotes the reaction [deoxynivalenol results in decreased activity of GSR protein]]]; fumonisin B1 promotes the reaction [deoxynivalenol results in decreased activity of GSR protein]; fumonisin B1 promotes the reaction [Zearalenone promotes the reaction [deoxynivalenol results in decreased activity of GSR protein]]; Zearalenone promotes the reaction [fumonisin B1 promotes the reaction [deoxynivalenol results in decreased activity of GSR protein]]
fumonisin B1 inhibits the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of IL17A protein]; fumonisin B1 metabolite inhibits the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of IL17A protein]
belnacasan inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of IL18 mRNA]; belnacasan inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of IL18 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of IL18 mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of IL18 protein]
[deoxynivalenol co-treated with fumonisin B1] results in decreased expression of IL1A mRNA; [deoxynivalenol co-treated with nivalenol co-treated with fumonisin B1] results in increased expression of IL1A mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL1A mRNA; [deoxynivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL1A mRNA; [nivalenol co-treated with fumonisin B1] results in increased expression of IL1A mRNA; [nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL1A mRNA; [Zearalenone co-treated with fumonisin B1] results in increased expression of IL1A mRNA fumonisin B1 results in increased expression of IL1A mRNA fumonisin B1 results in decreased expression of IL1A mRNA
[deoxynivalenol co-treated with fumonisin B1] results in increased expression of IL6 mRNA; [deoxynivalenol co-treated with nivalenol co-treated with fumonisin B1] results in increased expression of IL6 mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL6 mRNA; [deoxynivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL6 mRNA; [nivalenol co-treated with fumonisin B1] results in decreased expression of IL6 mRNA; [nivalenol co-treated with fumonisin B1] results in increased expression of IL6 mRNA; [nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL6 mRNA; [Zearalenone co-treated with fumonisin B1] results in increased expression of IL6 mRNA fumonisin B1 results in decreased expression of IL6 mRNA fumonisin B1 results in increased expression of IL6 mRNA
fumonisin B1 results in increased expression of IL1B mRNA [deoxynivalenol co-treated with fumonisin B1] results in increased expression of IL1B mRNA; [deoxynivalenol co-treated with nivalenol co-treated with fumonisin B1] results in increased expression of IL1B mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL1B mRNA; [deoxynivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL1B mRNA; [nivalenol co-treated with fumonisin B1] results in increased expression of IL1B mRNA; [nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL1B mRNA; [Zearalenone co-treated with fumonisin B1] results in increased expression of IL1B mRNA; belnacasan inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of IL1B mRNA]; belnacasan inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of IL1B mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of IL1B protein]
fumonisin B1 results in increased expression of MAPK10 mRNA 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [fumonisin B1 results in increased expression of MAPK10 mRNA]
fumonisin B1 results in increased expression of MAPK8 mRNA; fumonisin B1 results in increased expression of MAPK8 protein 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [fumonisin B1 results in increased expression of MAPK8 mRNA]; 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [fumonisin B1 results in increased expression of MAPK8 protein]
fumonisin B1 results in increased expression of MAPK9 mRNA 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [fumonisin B1 results in increased expression of MAPK9 mRNA]
fumonisin B1 results in increased expression of NFKB1 mRNA; fumonisin B1 results in increased expression of NFKB1 protein 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [fumonisin B1 results in increased expression of NFKB1 mRNA]; 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [fumonisin B1 results in increased expression of NFKB1 protein]
fumonisin B1 results in increased expression of SPP1 mRNA fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of SPP1 mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of SPP1 mRNA]
[deoxynivalenol co-treated with fumonisin B1] results in increased expression of TNF mRNA; [deoxynivalenol co-treated with Lipopolysaccharides co-treated with fumonisin B1] results in increased expression of TNF mRNA; [deoxynivalenol co-treated with Lipopolysaccharides co-treated with fumonisin B1] results in increased expression of TNF protein; [deoxynivalenol co-treated with nivalenol co-treated with fumonisin B1] results in increased expression of TNF mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of TNF mRNA; [deoxynivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of TNF mRNA; [nivalenol co-treated with fumonisin B1] results in increased expression of TNF mRNA; [nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of TNF mRNA; [Zearalenone co-treated with fumonisin B1] results in increased expression of TNF mRNA fumonisin B1 results in increased expression of TNF mRNA; fumonisin B1 results in increased expression of TNF protein
fumonisin B1 results in increased expression of TP53 mRNA [deoxynivalenol co-treated with fumonisin B1] results in increased expression of TP53 mRNA; Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [Zearalenone results in increased expression of TP53 mRNA]]; Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [fumonisin B1 results in increased expression of TP53 mRNA]]; fumonisin B1 inhibits the reaction [deoxynivalenol inhibits the reaction [Zearalenone results in increased expression of TP53 mRNA]]; fumonisin B1 promotes the reaction [Zearalenone results in increased expression of TP53 mRNA]; Zearalenone promotes the reaction [[deoxynivalenol co-treated with fumonisin B1] results in increased expression of TP53 mRNA]; Zearalenone promotes the reaction [fumonisin B1 results in increased expression of TP53 mRNA]
Gefitinib inhibits the reaction [FGF2 protein results in increased phosphorylation of FES protein]; Gefitinib inhibits the reaction [VEGFA protein results in increased phosphorylation of FES protein] Gefitinib results in decreased phosphorylation of FES protein
Glutathione inhibits the reaction [Cadmium Chloride results in decreased activity of IDH2 protein]; Glutathione inhibits the reaction [Cadmium results in decreased activity of IDH2 protein]
[Glutathione co-treated with Paraquat] results in increased expression of GSTA2 mRNA; Glutathione inhibits the reaction [Paraquat results in decreased expression of GSTA1 mRNA]
Betaine inhibits the reaction [Glyphosate results in increased expression of ATF4 mRNA]; Betaine inhibits the reaction [Glyphosate results in increased expression of ATF4 protein]
[Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] promotes the reaction [bisphenol A results in decreased expression of CAT protein]; [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of CAT mRNA; [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of CAT protein; Betaine inhibits the reaction [Glyphosate results in increased expression of CAT mRNA]
Betaine inhibits the reaction [Glyphosate results in decreased expression of CLDN1 mRNA]; Betaine inhibits the reaction [Glyphosate results in decreased expression of CLDN1 protein]
[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [bisphenol A results in decreased expression of DNMT3A mRNA]; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of DNMT3A mRNA
Betaine inhibits the reaction [Glyphosate results in increased expression of EIF2AK3 mRNA]; Betaine inhibits the reaction [Glyphosate results in increased expression of EIF2AK3 protein]
Betaine inhibits the reaction [Glyphosate results in increased expression of EIF2S1 mRNA]; Betaine inhibits the reaction [Glyphosate results in increased expression of EIF2S1 protein]
[Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of GPX1 mRNA; [bisphenol A co-treated with [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12]] results in increased expression of GPX1 mRNA
[Betaine co-treated with Choline co-treated with Folic Acid co-treated with bisphenol A] results in increased methylation of GYS1 promoter; [Betaine co-treated with Choline co-treated with Folic Acid] results in decreased expression of GYS1 mRNA; [Betaine co-treated with Choline co-treated with Folic Acid] results in increased methylation of GYS1 promoter
Betaine inhibits the reaction [Glyphosate results in increased expression of HSP90B1 mRNA]; Betaine inhibits the reaction [Glyphosate results in increased expression of HSP90B1 protein]
Betaine inhibits the reaction [Glyphosate results in increased expression of PCNA mRNA]; Betaine inhibits the reaction [Glyphosate results in increased expression of PCNA protein]
[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [bisphenol A results in decreased expression of SLC15A1 mRNA]; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [bisphenol A results in decreased methylation of SLC15A1 promoter]; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of SLC15A1 mRNA
[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid co-treated with bisphenol A] results in increased expression of SLC5A1 mRNA; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of SLC5A1 mRNA
Glyphosate results in increased expression of ATF4 mRNA; Glyphosate results in increased expression of ATF4 protein Betaine inhibits the reaction [Glyphosate results in increased expression of ATF4 mRNA]; Betaine inhibits the reaction [Glyphosate results in increased expression of ATF4 protein]
Glyphosate results in increased expression of CAT mRNA Betaine inhibits the reaction [Glyphosate results in increased expression of CAT mRNA] Glyphosate results in increased activity of CAT protein
Betaine inhibits the reaction [Glyphosate results in decreased expression of CLDN1 mRNA]; Betaine inhibits the reaction [Glyphosate results in decreased expression of CLDN1 protein] Glyphosate results in decreased expression of CLDN1 mRNA; Glyphosate results in decreased expression of CLDN1 protein
Glyphosate results in increased expression of CXCL8 mRNA pyrrolidine dithiocarbamic acid inhibits the reaction [Glyphosate results in increased expression of CXCL8 mRNA]
Betaine inhibits the reaction [Glyphosate results in increased expression of EIF2AK3 mRNA]; Betaine inhibits the reaction [Glyphosate results in increased expression of EIF2AK3 protein] Glyphosate results in increased expression of EIF2AK3 mRNA; Glyphosate results in increased expression of EIF2AK3 protein
Betaine inhibits the reaction [Glyphosate results in increased expression of EIF2S1 mRNA]; Betaine inhibits the reaction [Glyphosate results in increased expression of EIF2S1 protein] Glyphosate results in increased expression of EIF2S1 mRNA; Glyphosate results in increased expression of EIF2S1 protein
Glyphosate results in decreased expression of HMOX1 mRNA Glyphosate results in increased expression of and affects the localization of HMOX1 protein Glyphosate results in increased expression of HMOX1 mRNA
Glyphosate results in increased expression of HSP90B1 mRNA; Glyphosate results in increased expression of HSP90B1 protein Betaine inhibits the reaction [Glyphosate results in increased expression of HSP90B1 mRNA]; Betaine inhibits the reaction [Glyphosate results in increased expression of HSP90B1 protein]
Glyphosate results in increased expression of IL6 mRNA; Glyphosate results in increased expression of IL6 protein pyrrolidine dithiocarbamic acid inhibits the reaction [Glyphosate results in increased expression of IL6 mRNA] Glyphosate affects the secretion of IL6 protein
Glyphosate results in increased expression of IL1B mRNA; Glyphosate results in increased expression of IL1B protein pyrrolidine dithiocarbamic acid inhibits the reaction [Glyphosate results in increased expression of IL1B mRNA] Glyphosate results in increased secretion of IL1B protein
Betaine inhibits the reaction [Glyphosate results in increased expression of NFE2L2 mRNA]; Glyphosate results in increased expression of and affects the localization of NFE2L2 protein Glyphosate results in increased expression of NFE2L2 mRNA; Glyphosate results in increased expression of NFE2L2 protein
Glyphosate results in increased expression of PCNA mRNA; Glyphosate results in increased expression of PCNA protein Betaine inhibits the reaction [Glyphosate results in increased expression of PCNA mRNA]; Betaine inhibits the reaction [Glyphosate results in increased expression of PCNA protein]
Glyphosate results in decreased expression of SQSTM1 protein Acetylcysteine inhibits the reaction [Glyphosate results in decreased expression of SQSTM1 protein]
Ketoconazole inhibits the reaction [CYP3A29 protein results in increased chemical synthesis of 6 beta-hydroxytestosterone]; Ketoconazole inhibits the reaction [CYP3A29 protein results in increased hydroxylation of Testosterone]; Ketoconazole inhibits the reaction [CYP3A29 protein results in increased oxidation of Nifedipine]
Glutamine inhibits the reaction [bisphenol A results in increased expression of IL6 mRNA]; Glutamine inhibits the reaction [bisphenol A results in increased secretion of IL6 protein]
Glutamine inhibits the reaction [bisphenol A results in increased expression of TLR4 mRNA]; Glutamine inhibits the reaction [bisphenol A results in increased expression of TLR4 protein]
Glutamine inhibits the reaction [bisphenol A results in increased expression of TNF mRNA]; Glutamine inhibits the reaction [bisphenol A results in increased secretion of TNF protein]
Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of BAX mRNA]; Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of BAX protein]
Melatonin inhibits the reaction [deoxynivalenol results in decreased expression of BCL2 protein]; Melatonin inhibits the reaction [Malathion results in decreased expression of BCL2 mRNA] Melatonin results in increased expression of BCL2 mRNA
Melatonin results in increased expression of BECN1 protein Melatonin inhibits the reaction [deoxynivalenol results in increased expression of BECN1 protein]
Melatonin results in decreased expression of CASP3 mRNA Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of CASP3 mRNA]; Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of CASP3 protein]
Melatonin inhibits the reaction [tetrabromobisphenol A results in decreased expression of CASP8 mRNA]; Melatonin inhibits the reaction [tetrabromobisphenol A results in decreased expression of CASP8 protein]
Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of CASP9 mRNA]; Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of CASP9 protein]
Melatonin inhibits the reaction [deoxynivalenol results in decreased activity of CAT protein]; Melatonin inhibits the reaction [Malathion results in decreased expression of CAT mRNA] Melatonin results in increased activity of CAT protein
Melatonin inhibits the reaction [deoxynivalenol results in decreased expression of CLDN1 protein] Melatonin results in increased expression of CLDN1 protein
Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of MLKL mRNA]; Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of MLKL protein]
Melatonin inhibits the reaction [deoxynivalenol results in decreased phosphorylation of MTOR protein] Melatonin results in decreased phosphorylation of MTOR protein
Melatonin inhibits the reaction [Malathion results in decreased expression of PLIN2 mRNA]; Melatonin inhibits the reaction [Malathion results in decreased expression of PLIN2 protein]
Melatonin inhibits the reaction [Malathion results in decreased expression of PPARG mRNA]; Melatonin inhibits the reaction [Malathion results in decreased expression of PPARG protein]
Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of PTEN mRNA]; Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of PTEN protein]
Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of RIPK1 mRNA]; Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of RIPK1 protein]
Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of RIPK3 mRNA]; Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of RIPK3 protein]
Melatonin results in increased expression of TJP1 protein Melatonin inhibits the reaction [deoxynivalenol results in decreased expression of TJP1 protein]
mesulergine binds to HTR2C protein 8-fluoro-12-(4-methylpiperazin-1-yl)-6H-(1)benzothieno(2,3-b)(1,5)benzodiazepine inhibits the reaction [mesulergine binds to HTR2C protein]
[N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in decreased expression of CLDN1 mRNA]; [SB 203580 co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in decreased expression of CLDN1 mRNA]; theanine inhibits the reaction [Lipopolysaccharides results in decreased expression of CLDN1 mRNA]
[N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; [SB 203580 co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; theanine inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]
[SB 203580 co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in increased expression of MAPK14 mRNA]; theanine inhibits the reaction [Lipopolysaccharides results in increased expression of MAPK14 mRNA]
[N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in increased expression of NLRP3 mRNA]; [SB 203580 co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in increased expression of NLRP3 mRNA]; theanine inhibits the reaction [Lipopolysaccharides results in increased expression of NLRP3 mRNA]
[N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in decreased expression of OCLN mRNA]; [SB 203580 co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in decreased expression of OCLN mRNA]; theanine inhibits the reaction [Lipopolysaccharides results in decreased expression of OCLN mRNA]
N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [Linoleic Acid promotes the reaction [TNF protein results in increased activity of ANXA5 protein]]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein promotes the reaction [Linoleic Acid results in increased activity of ANXA5 protein]]; Zinc Acetate inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [Linoleic Acid promotes the reaction [TNF protein results in increased activity of ANXA5 protein]]]; Zinc Acetate inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein promotes the reaction [Linoleic Acid results in increased activity of ANXA5 protein]]]
N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [Linoleic Acid promotes the reaction [TNF protein results in increased activity of CASP3 protein]]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [Linoleic Acid results in increased activity of CASP3 protein]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein promotes the reaction [Linoleic Acid results in increased activity of CASP3 protein]]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein results in increased activity of CASP3 protein]; Zinc Acetate inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [Linoleic Acid promotes the reaction [TNF protein results in increased activity of CASP3 protein]]]; Zinc Acetate inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [Linoleic Acid results in increased activity of CASP3 protein]]; Zinc Acetate inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein results in increased activity of CASP3 protein]]; Zinc Acetate promotes the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein promotes the reaction [Linoleic Acid results in increased activity of CASP3 protein]]]
[Zinc co-treated with 2,4-thiazolidinedione] inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein results in increased expression of IL6 mRNA]]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein results in increased expression of IL6 mRNA]; Zinc inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in increased expression of IL6 protein]
N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in decreased expression of PPARA mRNA Zinc Acetate inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in decreased expression of PPARA mRNA]
N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [Zinc results in increased expression of and results in increased activity of PPARG protein]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [Zinc results in increased expression of PPARG mRNA]
N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in increased expression of PTGS2 mRNA; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in increased expression of PTGS2 protein caffeic acid phenethyl ester inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in increased expression of PTGS2 protein]; Zinc Acetate inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in increased expression of PTGS2 mRNA]
[2,4-thiazolidinedione co-treated with Zinc] inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in increased activity of TNF protein]; [ciprofibrate co-treated with Zinc] inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in increased activity of TNF protein]; [Fenofibrate co-treated with Zinc] inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in increased activity of TNF protein]; [Troglitazone co-treated with Zinc] inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in increased activity of TNF protein]; [Zinc co-treated with 2,4-thiazolidinedione] inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein results in increased expression of IL6 mRNA]]; [Zinc co-treated with 2,4-thiazolidinedione] inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein results in increased expression of VCAM1 mRNA]]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [Linoleic Acid promotes the reaction [TNF protein results in increased activity of ANXA5 protein]]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [Linoleic Acid promotes the reaction [TNF protein results in increased activity of CASP3 protein]]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein promotes the reaction [Linoleic Acid results in increased activity of ANXA5 protein]]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein promotes the reaction [Linoleic Acid results in increased activity of CASP3 protein]]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein results in increased activity of CASP3 protein]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein results in increased expression of IL6 mRNA]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein results in increased expression of VCAM1 mRNA]; Zinc Acetate inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [Linoleic Acid promotes the reaction [TNF protein results in increased activity of ANXA5 protein]]]; Zinc Acetate inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [Linoleic Acid promotes the reaction [TNF protein results in increased activity of CASP3 protein]]]; Zinc Acetate inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein promotes the reaction [Linoleic Acid results in increased activity of ANXA5 protein]]]; Zinc Acetate inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein results in increased activity of CASP3 protein]]; Zinc Acetate promotes the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein promotes the reaction [Linoleic Acid results in increased activity of CASP3 protein]]]
[Zinc co-treated with 2,4-thiazolidinedione] inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein results in increased expression of VCAM1 mRNA]]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein results in increased expression of VCAM1 mRNA]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Brimonidine Tartrate results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased expression of IL6 protein N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Amphotericin B results in increased expression of IL6 protein]
Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX protein]; Acetylcysteine inhibits the reaction [Cadmium results in increased expression of BAX protein]
[Acetylcysteine co-treated with fumonisin B1 co-treated with deoxynivalenol] results in increased expression of BCL2 protein; [Acetylcysteine co-treated with fumonisin B1] results in increased expression of BCL2 protein; [Acetylcysteine co-treated with Zearalenone co-treated with deoxynivalenol] results in increased expression of BCL2 protein; [Acetylcysteine co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of BCL2 protein; [Acetylcysteine co-treated with Zearalenone] results in increased expression of BCL2 protein; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in decreased expression of BCL2 mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 protein]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with Zearalenone] results in decreased expression of BCL2 mRNA]; Acetylcysteine inhibits the reaction [Cadmium results in decreased expression of BCL2 protein]; Acetylcysteine inhibits the reaction [deoxynivalenol results in decreased expression of BCL2 protein]; Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [Zearalenone results in decreased expression of BCL2 mRNA]]
[Acetylcysteine co-treated with Zearalenone] results in decreased expression of CASP3 protein; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein modified form]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with Zearalenone] promotes the reaction [deoxynivalenol results in increased expression of CASP3 protein]]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with Zearalenone] results in increased expression of CASP3 protein]; Acetylcysteine inhibits the reaction [Cadmium Chloride results in increased activity of CASP3 protein]; Acetylcysteine inhibits the reaction [Cadmium results in increased activity of CASP3 protein]; Acetylcysteine inhibits the reaction [deoxynivalenol promotes the reaction [[fumonisin B1 co-treated with Zearalenone] results in increased expression of CASP3 mRNA]]; Acetylcysteine inhibits the reaction [deoxynivalenol promotes the reaction [Zearalenone results in increased expression of CASP3 mRNA]]; Acetylcysteine inhibits the reaction [deoxynivalenol results in increased expression of CASP3 protein]; Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of CASP3 mRNA]]; Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [deoxynivalenol results in increased expression of CASP3 mRNA]]; Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [deoxynivalenol results in increased expression of CASP3 protein]]
Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein modified form]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein]; Acetylcysteine inhibits the reaction [Cadmium results in increased activity of CASP9 protein]
Acetylcysteine inhibits the reaction [deoxynivalenol promotes the reaction [[Zearalenone co-treated with fumonisin B1] results in increased expression of CYCS mRNA]]; Acetylcysteine inhibits the reaction [deoxynivalenol promotes the reaction [Zearalenone results in increased expression of CYCS mRNA]]; Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [deoxynivalenol promotes the reaction [Zearalenone results in increased expression of CYCS mRNA]]]; Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [[deoxynivalenol co-treated with fumonisin B1] results in increased expression of CYCS mRNA]]
Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [deoxynivalenol results in decreased activity of GSR protein]]; Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [Zearalenone promotes the reaction [deoxynivalenol results in decreased activity of GSR protein]]]; Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [fumonisin B1 promotes the reaction [deoxynivalenol results in decreased activity of GSR protein]]]
Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [Zearalenone results in increased expression of TP53 mRNA]]; Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [fumonisin B1 results in increased expression of TP53 mRNA]]; Acetylcysteine promotes the reaction [deoxynivalenol inhibits the reaction [Zearalenone results in increased expression of TP53 mRNA]]
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of AKT1 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sodium arsenite results in increased degradation of AKT1 protein]
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sodium arsenite results in increased degradation of NOS3 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NOS3 protein
2-aminoacetophenone inhibits the reaction [[CYP2A19 protein results in increased hydroxylation of coumarin] which results in increased chemical synthesis of 7-hydroxycoumarin]; 2-aminoacetophenone inhibits the reaction [CYP2A19 protein results in increased hydroxylation of coumarin]
2-aminoacetophenone inhibits the reaction [[CYP2E1 protein results in increased hydroxylation of 4-nitrophenol] which results in increased chemical synthesis of 4-nitrocatechol]; 2-aminoacetophenone inhibits the reaction [CYP2E1 protein results in increased hydroxylation of 4-nitrophenol]
ochratoxin A results in increased expression of APAF1 mRNA; ochratoxin A results in increased expression of APAF1 protein fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of APAF1 mRNA]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of APAF1 protein]
ATG5 protein affects the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; ATG5 protein affects the reaction [ochratoxin A results in increased cleavage of PARP1 protein] ochratoxin A results in increased expression of ATG5 protein
[fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX mRNA; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX protein; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX protein]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of BAX mRNA]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of BAX protein]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of BAX mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of BAX protein]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX mRNA] ochratoxin A results in increased expression of BAX mRNA; ochratoxin A results in increased expression of BAX protein
[fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 mRNA; [fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 protein; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 protein]; fumonisin B1 promotes the reaction [ochratoxin A results in decreased expression of BCL2 mRNA]; fumonisin B1 promotes the reaction [ochratoxin A results in decreased expression of BCL2 protein]; ochratoxin A promotes the reaction [fumonisin B1 results in decreased expression of BCL2 mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in decreased expression of BCL2 protein]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 mRNA]; TLR4 protein affects the reaction [ochratoxin A affects the expression of BCL2 mRNA] ochratoxin A results in decreased expression of BCL2 mRNA; ochratoxin A results in decreased expression of BCL2 protein
BECN1 protein affects the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; BECN1 protein affects the reaction [ochratoxin A results in increased cleavage of PARP1 protein] ochratoxin A results in increased expression of BECN1 protein
Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of and results in increased cleavage of CASP1 protein]; ochratoxin A results in increased expression of and results in increased cleavage of CASP1 protein; Taurine inhibits the reaction [ochratoxin A results in increased expression of and results in increased cleavage of CASP1 protein]
3-methyladenine promotes the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 mRNA; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein modified form; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein modified form]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein]; ATG5 protein affects the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; BECN1 protein affects the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; Chloroquine promotes the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; fumonisin B1 promotes the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP3 mRNA]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP3 protein modified form]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP3 protein]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP3 mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP3 protein modified form]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP3 protein]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 mRNA]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein modified form]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein] ochratoxin A results in increased expression of CASP3 mRNA; ochratoxin A results in increased expression of CASP3 protein; ochratoxin A results in increased expression of CASP3 protein modified form
[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 mRNA; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein modified form; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein modified form]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP9 mRNA]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP9 protein modified form]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP9 protein]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP9 mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP9 protein modified form]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP9 protein]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 mRNA]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein modified form]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein] ochratoxin A results in increased expression of CASP9 mRNA; ochratoxin A results in increased expression of CASP9 protein; ochratoxin A results in increased expression of CASP9 protein modified form
ochratoxin A results in decreased expression of CAT mRNA; ochratoxin A results in decreased expression of CAT protein Acetylcysteine inhibits the reaction [ochratoxin A results in decreased expression of CAT mRNA]; Taurine inhibits the reaction [ochratoxin A results in decreased expression of CAT mRNA]
ochratoxin A results in increased expression of DNMT1 mRNA; ochratoxin A results in increased expression of DNMT1 protein Decitabine inhibits the reaction [ochratoxin A results in increased expression of DNMT1 mRNA]; Decitabine inhibits the reaction [ochratoxin A results in increased expression of DNMT1 protein]
ochratoxin A results in decreased expression of GCLC mRNA ochratoxin A inhibits the reaction [sulforaphane results in increased expression of GCLC mRNA]
ochratoxin A results in decreased expression of GPX1 mRNA Acetylcysteine inhibits the reaction [ochratoxin A results in decreased expression of GPX1 mRNA]; Taurine inhibits the reaction [ochratoxin A results in decreased expression of GPX1 mRNA]
ochratoxin A results in decreased expression of GPX4 mRNA Acetylcysteine inhibits the reaction [ochratoxin A results in decreased expression of GPX4 mRNA]; Taurine inhibits the reaction [ochratoxin A results in decreased expression of GPX4 mRNA]
Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of GSDMD protein]; Taurine inhibits the reaction [ochratoxin A results in increased expression of GSDMD protein]
alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [ochratoxin A results in increased expression of H2AX protein]; Decitabine inhibits the reaction [ochratoxin A results in increased expression of H2AX protein]; STAT3 protein affects the reaction [ochratoxin A results in increased expression of H2AX protein]
Panobinostat inhibits the reaction [ochratoxin A results in increased expression of HDAC1 mRNA]; Panobinostat inhibits the reaction [ochratoxin A results in increased expression of HDAC1 protein] ochratoxin A results in increased expression of HDAC1 mRNA; ochratoxin A results in increased expression of HDAC1 protein
ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of IL1A mRNA]; TLR4 protein affects the reaction [ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of IL1A mRNA]]
ochratoxin A results in increased expression of IL6 mRNA NFE2L2 protein affects the reaction [ochratoxin A results in increased expression of IL6 mRNA]
ochratoxin A results in decreased expression of GSTA1 mRNA ochratoxin A inhibits the reaction [sulforaphane results in increased expression of GSTA1 mRNA]
Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of IL1B protein]; Taurine inhibits the reaction [ochratoxin A results in increased expression of IL1B protein]
ochratoxin A results in increased phosphorylation of MAPK1 protein ochratoxin A inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]
ochratoxin A inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein] ochratoxin A results in increased phosphorylation of MAPK3 protein
ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of MYD88 mRNA]; ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of MYD88 protein]
ochratoxin A results in decreased expression of NEIL1 mRNA alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [ochratoxin A results in decreased expression of NEIL1 mRNA]; Decitabine inhibits the reaction [ochratoxin A results in decreased expression of NEIL1 mRNA]; STAT3 protein affects the reaction [ochratoxin A results in decreased expression of NEIL1 mRNA]
alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [ochratoxin A results in decreased expression of NEIL3 mRNA]; Decitabine inhibits the reaction [ochratoxin A results in decreased expression of NEIL3 mRNA]; STAT3 protein affects the reaction [ochratoxin A results in decreased expression of NEIL3 mRNA]
ochratoxin A results in decreased activity of NFE2L2 protein NFE2L2 protein affects the reaction [ochratoxin A results in increased expression of IL6 mRNA]; NFE2L2 protein affects the reaction [ochratoxin A results in increased expression of TGFB1 mRNA]; NFE2L2 protein affects the reaction [ochratoxin A results in increased expression of TP53 protein]; ochratoxin A inhibits the reaction [sulforaphane affects the localization of NFE2L2 protein]; ochratoxin A inhibits the reaction [sulforaphane results in increased activity of NFE2L2 protein]; ochratoxin A inhibits the reaction [sulforaphane results in increased expression of NFE2L2 mRNA] ochratoxin A results in decreased expression of NFE2L2 mRNA
Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of NLRP3 protein]; Taurine inhibits the reaction [ochratoxin A results in increased expression of NLRP3 protein]
ochratoxin A results in increased expression of INOS mRNA Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of INOS mRNA]; Taurine inhibits the reaction [ochratoxin A results in decreased expression of INOS mRNA]
ochratoxin A results in decreased expression of OGG1 mRNA alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [ochratoxin A results in decreased expression of OGG1 mRNA]; Decitabine inhibits the reaction [ochratoxin A results in decreased expression of OGG1 mRNA]; STAT3 protein affects the reaction [ochratoxin A results in decreased expression of OGG1 mRNA]
ochratoxin A results in increased cleavage of PARP1 protein ochratoxin A results in increased expression of PARP1 protein 3-methyladenine promotes the reaction [ochratoxin A results in increased cleavage of PARP1 protein]; ATG5 protein affects the reaction [ochratoxin A results in increased cleavage of PARP1 protein]; BECN1 protein affects the reaction [ochratoxin A results in increased cleavage of PARP1 protein]; Chloroquine promotes the reaction [ochratoxin A results in increased cleavage of PARP1 protein]
Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of PTGS2 mRNA]; Taurine inhibits the reaction [ochratoxin A results in decreased expression of PTGS2 mRNA]
ochratoxin A results in increased expression of PYCARD protein Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of PYCARD protein]; Taurine inhibits the reaction [ochratoxin A results in increased expression of PYCARD protein]
ochratoxin A results in increased expression of SOCS3 mRNA; ochratoxin A results in increased expression of SOCS3 protein Decitabine promotes the reaction [ochratoxin A results in increased expression of SOCS3 mRNA]; Decitabine promotes the reaction [ochratoxin A results in increased expression of SOCS3 protein]
fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of SPP1 mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of SPP1 mRNA]
Decitabine inhibits the reaction [ochratoxin A results in increased phosphorylation of STAT3 protein]; STAT3 protein affects the reaction [ochratoxin A results in decreased expression of NEIL1 mRNA]; STAT3 protein affects the reaction [ochratoxin A results in decreased expression of NEIL3 mRNA]; STAT3 protein affects the reaction [ochratoxin A results in decreased expression of OGG1 mRNA]; STAT3 protein affects the reaction [ochratoxin A results in increased expression of H2AX protein]
ochratoxin A results in increased expression of TGFB1 mRNA NFE2L2 protein affects the reaction [ochratoxin A results in increased expression of TGFB1 mRNA]; sulforaphane inhibits the reaction [ochratoxin A results in increased expression of TGFB1 mRNA]
ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of TLR4 mRNA]; ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of TLR4 protein]; TLR4 protein affects the reaction [ochratoxin A affects the expression of BCL2 mRNA]; TLR4 protein affects the reaction [ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of IL1A mRNA]]; TLR4 protein affects the reaction [ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]
ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; TLR4 protein affects the reaction [ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]] ochratoxin A results in increased secretion of TNF protein
omega-Conotoxin GVIA inhibits the reaction [ADCYAP1 protein alternative form results in decreased susceptibility to 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid]
omega-Conotoxin GVIA inhibits the reaction [Enkephalin, Ala(2)-MePhe(4)-Gly(5)- inhibits the reaction [OPRM1 protein results in increased transport of Barium]]
omega-Conotoxin GVIA inhibits the reaction [VIP protein results in decreased susceptibility to 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid]
Panobinostat inhibits the reaction [ochratoxin A results in increased expression of HDAC1 mRNA]; Panobinostat inhibits the reaction [ochratoxin A results in increased expression of HDAC1 protein]
caffeic acid phenethyl ester inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in increased expression of PTGS2 protein]
Raloxifene Hydrochloride results in decreased expression of ESR1 protein alternative form Raloxifene Hydrochloride affects the expression of ESR1 protein Raloxifene Hydrochloride metabolite binds to ESR1 protein
Raloxifene Hydrochloride results in increased phosphorylation of NOS3 protein Raloxifene Hydrochloride affects the expression of NOS3 mRNA Fulvestrant inhibits the reaction [Raloxifene Hydrochloride results in increased phosphorylation of NOS3 protein] Raloxifene Hydrochloride results in decreased expression of NOS3 protein
Masoprocol inhibits the reaction [Ritonavir results in decreased expression of NOS3 mRNA]; Masoprocol inhibits the reaction [Ritonavir results in decreased expression of NOS3 protein]; Ritonavir results in decreased expression of and results in decreased activity of NOS3 protein Ritonavir results in decreased expression of NOS3 mRNA; Ritonavir results in decreased expression of NOS3 protein
Buthionine Sulfoximine inhibits the reaction [sulforaphane inhibits the reaction [Cisplatin results in decreased activity of GCLC protein]] Buthionine Sulfoximine results in decreased activity of GCLC protein
2,3-dimethoxy-1,4-naphthoquinone inhibits the reaction [S-Nitrosoglutathione results in increased expression of HIF1A protein]; AKT1 protein mutant form inhibits the reaction [S-Nitrosoglutathione results in increased expression of HIF1A protein]; Genistein inhibits the reaction [S-Nitrosoglutathione results in increased expression of HIF1A protein]; PIK3R1 protein mutant form inhibits the reaction [S-Nitrosoglutathione results in increased expression of HIF1A protein]; Wortmannin inhibits the reaction [S-Nitrosoglutathione results in increased expression of HIF1A protein]
Serotonin results in increased expression of FOS mRNA; Serotonin results in increased expression of FOS protein sarpogrelate inhibits the reaction [Serotonin results in increased expression of FOS mRNA]; sarpogrelate inhibits the reaction [Serotonin results in increased expression of FOS protein]
sarpogrelate inhibits the reaction [Serotonin results in increased expression of JUN mRNA]; sarpogrelate inhibits the reaction [Serotonin results in increased expression of JUN protein] Serotonin results in increased expression of JUN mRNA; Serotonin results in increased expression of JUN protein
Serotonin results in increased phosphorylation of MAPK1 protein sarpogrelate inhibits the reaction [Serotonin results in increased phosphorylation of MAPK1 protein]
sulforaphane results in increased expression of GCLC mRNA sulforaphane results in increased activity of GCLC protein Buthionine Sulfoximine inhibits the reaction [sulforaphane inhibits the reaction [Cisplatin results in decreased activity of GCLC protein]]; ochratoxin A inhibits the reaction [sulforaphane results in increased expression of GCLC mRNA]; sulforaphane inhibits the reaction [Cisplatin results in decreased activity of GCLC protein]
NFE2L2 protein affects the reaction [sulforaphane results in increased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [sulforaphane results in increased expression of NQO1 protein]; ochratoxin A inhibits the reaction [sulforaphane affects the localization of NFE2L2 protein]; ochratoxin A inhibits the reaction [sulforaphane results in increased activity of NFE2L2 protein]; ochratoxin A inhibits the reaction [sulforaphane results in increased expression of NFE2L2 mRNA]; sulforaphane results in increased expression of and results in increased activity of NFE2L2 protein
Dicumarol inhibits the reaction [sulforaphane inhibits the reaction [Cisplatin results in decreased activity of NQO1 protein]]; NFE2L2 protein affects the reaction [sulforaphane results in increased expression of NQO1 protein]; sulforaphane inhibits the reaction [Cisplatin results in decreased activity of NQO1 protein] sulforaphane results in increased activity of NQO1 protein
SLCO1A2 protein results in increased uptake of Taurocholic Acid Amoxicillin inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]; cefquinome inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]; Clarithromycin inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]; daidzein inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]; Doxycycline inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]; epigallocatechin gallate inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]; Erythromycin inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]; Genistein inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]; naringin inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]; Oxytetracycline inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]; Penicillins inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]; Tetracycline inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]; tilmicosin inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]; Tylosin inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]
[ursodoxicoltaurine co-treated with Cadmium] results in increased expression of TNFAIP6 mRNA; ursodoxicoltaurine inhibits the reaction [Cadmium results in decreased expression of TNFAIP6 mRNA]
3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer inhibits the reaction [AGT protein results in increased secretion of Aldosterone]
3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer inhibits the reaction [OPRK1 protein results in increased transport of Barium]